ZA201309480B - Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders - Google Patents

Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Info

Publication number
ZA201309480B
ZA201309480B ZA2013/09480A ZA201309480A ZA201309480B ZA 201309480 B ZA201309480 B ZA 201309480B ZA 2013/09480 A ZA2013/09480 A ZA 2013/09480A ZA 201309480 A ZA201309480 A ZA 201309480A ZA 201309480 B ZA201309480 B ZA 201309480B
Authority
ZA
South Africa
Prior art keywords
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
receptor mediated
Prior art date
Application number
ZA2013/09480A
Other languages
English (en)
Inventor
Kelly Yvonne Conway
Michael John Quayle
Helena Ingemo Andersson
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Publication of ZA201309480B publication Critical patent/ZA201309480B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/09480A 2011-06-29 2013-12-13 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders ZA201309480B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
ZA201309480B true ZA201309480B (en) 2015-10-28

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/09480A ZA201309480B (en) 2011-06-29 2013-12-13 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Country Status (16)

Country Link
EP (1) EP2726464A1 (es)
JP (1) JP2014527955A (es)
KR (1) KR20140036230A (es)
CN (1) CN103814015A (es)
AR (1) AR086818A1 (es)
AU (1) AU2012277514A1 (es)
BR (1) BR112013031759A2 (es)
CA (1) CA2839398A1 (es)
IN (1) IN2014MN00023A (es)
MX (1) MX2013014566A (es)
RU (1) RU2013153466A (es)
SG (1) SG195309A1 (es)
TW (1) TW201305115A (es)
UY (1) UY34170A (es)
WO (1) WO2013001294A1 (es)
ZA (1) ZA201309480B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
WO2022114105A1 (ja) * 2020-11-27 2022-06-02 ミライラボバイオサイエンス株式会社 高純度βニコチンアミドモノヌクレオチド(NMN)及びその製造方法
CN116283781A (zh) * 2022-12-16 2023-06-23 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
ES2535701T3 (es) 2010-07-21 2015-05-14 Astrazeneca Ab Inhalador
BR112013001342A2 (pt) 2010-07-21 2016-05-17 Astrazeneca Ab dispositivo

Also Published As

Publication number Publication date
IN2014MN00023A (es) 2015-06-12
JP2014527955A (ja) 2014-10-23
SG195309A1 (en) 2013-12-30
KR20140036230A (ko) 2014-03-25
CN103814015A (zh) 2014-05-21
TW201305115A (zh) 2013-02-01
MX2013014566A (es) 2014-09-25
RU2013153466A (ru) 2015-08-10
CA2839398A1 (en) 2013-01-03
WO2013001294A1 (en) 2013-01-03
BR112013031759A2 (pt) 2016-12-13
AR086818A1 (es) 2014-01-22
AU2012277514A1 (en) 2014-01-09
EP2726464A1 (en) 2014-05-07
UY34170A (es) 2013-01-31

Similar Documents

Publication Publication Date Title
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
HK1199030A1 (zh) 用於治療 受體相關疾病的取代的 -苯基吡啶
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
SG11201401202YA (en) Antagonists of il17c for the treatment of inflammatory disorders
HK1194665A1 (zh) 用於治療神經系統病症的組合物
ME02180B (me) Supstanca korisna za lečenje poremećaja metabolizma lipida
ZA201309480B (en) Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
HK1194733A1 (zh) 製備 -酰基- -苯基磺酰基脯氨酰胺衍生物的方法及中間體
ZA201403736B (en) Process for the preparation of sterol derivatives
EP2675275A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
EP2673363A4 (en) TREATMENT OF ANGIOGENESIS DISORDERS
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HRP20160767T1 (hr) Postupak za pripremu kristalnog oblika i agomelatina
GB201119458D0 (en) Compositions for treatment of sleep disorders
PL393723A1 (pl) Sposób oczyszczania 3-podstawionych pochodnych ß- diketonów